Biodexa PharmaceuticalsBDRX
13F holders, Q2 2026 (June 30)1holders −6
0new positions
1sold out
$2.67avg. 13F price*
At the end of Q2 2026, 1 institutions reported holding Biodexa Pharmaceuticals PLC (BDRX) in their 13F filings, down 6 from Q1 2026. 0 opened new positions and 1 sold out. The largest holder was Rhumbline Advisers ($8).
- Company
- Biodexa Pharmaceuticals PLC
- CUSIP
- 59564R880
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $159K |
All 13F filers, Q1 2026 → Q2 2026: 257,488 shares sold, net −257,488 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Rhumbline Advisers | 0.00% | Reduce -84.2% | 3 | $8 |
"% of holder's portfolio" is BDRX's weight in each manager's 13F, not the share of Biodexa Pharmaceuticals PLC the manager owns.